Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2025 Apr 24;15:1588290. doi: 10.3389/fonc.2025.1588290

Corrigendum: Metabolic-imaging of human glioblastoma live tumors: a new precision-medicine approach to predict tumor treatment response early

Mariangela Morelli 1,*, Francesca Lessi 1, Serena Barachini 1,2, Romano Liotti 1,3, Nicola Montemurro 4, Paolo Perrini 4, Orazio Santo Santonocito 5, Carlo Gambacciani 5, Matija Snuderl 6, Francesco Pieri 5, Filippo Aquila 5, Azzurra Farnesi 5, Antonio Giuseppe Naccarato 7, Paolo Viacava 8, Francesco Cardarelli 9, Gianmarco Ferri 9,10, Paul Mulholland 11, Diego Ottaviani 11, Fabiola Paiar 12, Gaetano Liberti 4, Francesco Pasqualetti 12,13, Michele Menicagli 1, Paolo Aretini 14, Giovanni Signore 10, Sara Franceschi 1, Chiara Maria Mazzanti 1,*
PMCID: PMC12059221  PMID: 40342826

In the published article, there was an error in Figure 1 as published. The two figures above and below in Figures 1K-L , related to SOX2 staining, are part of a series of photographs aimed at demonstrating that GB explants—small tissue fragments approximately 300 µm in size—retain the original cytoarchitecture of the tissue from which they are derived (surgery tissue). The upper figure represents an image of the surgery tissue, while the lower figure shows the corresponding small explant (GB-EXP) derived from it. The SOX2 staining was specifically performed to add further evidence of the preserved representation of tumor components within the GB explant, a conclusion also supported by other images in the series (GFAP; CD105,CD33).

Figure 1.

Figure 1

GB-EXPs cultures (A) Experimental design. (B) A surgery tumor sample. (C) GB-EXP embedded in matrigel. (D) H&E staining of a surgery GB tissue. (E) Live/dead staining of a GB-EXP at 2 weeks after culturing. (F, G) Ki67 immunostaining of GB-EXPs in suspension at 0 week and 2 weeks. (H) Ki67 mRNA expression analysis of 13 GB case-derived GB-EXPs at 0 and 2 weeks. Graph represents mean ± s.d. of triplicated measures. (I) Representative brightfield and area size images of a GB-EXP in matrigel at 0 week, 1 week and 2 weeks. (J) Size analysis 20 GB case-derived GB-EXPs at 0, 1 and 2 weeks. (K, L) Immunofluorescence assays of surgery GB tissue (K) and GB-EXPs (L). GFAP (astrocytes), IBA1 (microglia), SOX2 (stem cells), CD105 (endothelial cells) and CD3 (lymphocytes). WTA, Whole Transcriptome Analysis; WEA, Whole Exome Analysis; FC, Flow Cytometry; H&E, Hematoxylin, and Eosin; MGMT, MGMT promoter methylation analysis.

We acknowledge an error of duplication in the figures related to SOX2, as the upper image is, in fact, a photo of the same explant but with a slightly shifted area. We deeply regret this misplacement and are providing the correct image of the tumor stained with SOX2.The corrected Figure 1 and its legend appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES